Cell-free DNA diagnostics: current and emerging applications in oncology.

Cell-free DNA diagnostics: current and emerging applications in oncology.

Publication date: Apr 15, 2019

Liquid biopsy is a noninvasive dynamic approach for monitoring disease over time. It offers advantages including limited risks of blood sampling, opportunity for more frequent sampling, lower costs and theoretically non-biased sampling compared with tissue biopsy. There is a high degree of concordance between circulating tumor DNA mutations versus primary tumor mutations. Remote sampling of circulating tumor DNA can serve as viable option in clinical diagnostics. Here, we discuss the progress toward broad adoption of liquid biopsy as a diagnostic tool and discuss knowledge gaps that remain to be addressed.

Muluhngwi, P., Valdes, R., Fernandez-Botran, R., Burton, E., Williams, B., and Linder, M.W. Cell-free DNA diagnostics: current and emerging applications in oncology. 22314. 2019 Pharmacogenomics.

Concepts Keywords
Blood Neoplasm
Concordance Liquid biopsy
Oncology Circulating tumor DNA
Pharmacogenomics Circulating free DNA
Primary Tumor Medical signs
Tissue Biopsy Anatomical pathology
Tumor Oncology
Biopsy
DNA
Branches of biology
Clinical medicine
Medicine
Primary tumor
Tumor

Semantics

Type Source Name
gene UNIPROT FBN1
disease DOID Neoplasm
disease DOID NSCLC
pathway BSID Methylation
pathway BSID Melanoma
disease DOID melanoma
disease MESH melanoma
pathway BSID Colorectal cancer
disease DOID colorectal cancer
disease MESH colorectal cancer
disease MESH tumor

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *